Oncology Central

News round-up: Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed

NICE gives green light to novel immunotherapy for most common lung cancer

Patients with advanced NSCLC, whose disease has progressed following standard chemotherapy, can now access the immunotherapy Tecentriq® (atezolizumab) via the NHS in England and Wales. The novel immunotherapy has significantly extended the lives of patients with advanced NSCLC versus chemotherapy, with fewer side effects.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.